Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04365062
Other study ID # FPA-ISR
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2018
Est. completion date December 2021

Study information

Verified date July 2019
Source Xuanwu Hospital, Beijing
Contact li yang
Phone 17198643706
Email 1093075829@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized study comparing Excimer laser and drug coated balloon Versus Excimer laser and plain balloon versus plain balloon and drug coated balloon to Treat femoropopliteal in-stent restenosis


Description:

This is a randomized study comparing Excimer laser and drug coated balloon Versus Excimer laser and plain balloon versus plain balloon and drug coated balloon to Treat femoropopliteal in-stent restenosis


Recruitment information / eligibility

Status Recruiting
Enrollment 160
Est. completion date December 2021
Est. primary completion date December 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

Provides written informed consent Willing to comply with follow-up evaluations at specified times Has claudication or rest pain due to peripheral arterial In-stent restenosis Disease located within the femoropopliteal artery Patient has a In-stent restenosis lesion(s) with >50% stenosis documented angiographically Patient has symptoms of peripheral arterial disease classified as Rutherford Category 2 or greater.

Exclusion Criteria:

They were excluded if they had one or more of the following: 1. Acute or subacute lower limb ischemia; 2. Severe calcification lesions; 3. Total occlusions lesions more significant than 10 cm or total occlusion lesions with a suspicion of subintimal wire recanalization 4. untreated ipsilateral iliac artery stenosis>70%, or the distal runoff artery <1 root; 5. Previously lower extremity intervention or surgical graft artery bypass; 6. Severe renal insufficiency, creatinine level greater than 2.5 mg/dL; 7. The patient's platelet count is less than 100,000/uL, antiplatelet or anticoagulant contraindications to required medications; 8. Patients with immune system diseases or malignant tumours; 9. ongoing active infection 10. decompensated congestive heart failure or acute coronary syndrome; 11. Unwillingness to return for future follow-up visits

Study Design


Intervention

Device:
Excimer laser and drug coated balloon
Excimer laser and drug coated balloon
Excimer laser and plain balloon
Excimer laser and plain balloon
plain balloon and drug coated balloon
plain balloon and drug coated balloon

Locations

Country Name City State
China Gu Yong Quan Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Xuanwu Hospital, Beijing

Country where clinical trial is conducted

China, 

References & Publications (1)

Yongquan G, Lianrui G, Lixing Q, Xuefeng L, Zhu T, Shijun C, Yingfeng W, Jianming G, Jian Z, Zhonggao W. Plaque excision in the management of lower-limb ischemia of atherosclerosis and in-stent restenosis with the SilverHawk atherectomy catheter. Int Angiol. 2013 Aug;32(4):362-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Patency Rate Primary patency is defined as no significant reduction of flow detectable by Duplex ultrasound through the index lesion and no further clinically driven target vessel revascularization performed in the interim. Significant reduction of flow is binary restenosis defined as the diameter stenosis >50% with a peak systolic velocity ratio >2.4 as measured by Duplex ultrasound. 12 months
Secondary Technical success Technical success is defined as residual stenosis less than 30% by final angiography and/or a flow-limiting dissection. 1 day
Secondary freedom from clinically-driven TLR it is defined as freedom from clinically-driven target lesion revascularization 12 months
Secondary Major Adverse Events Major adverse events included death, index limb ischemia, index limb amputation, and significant embolic events, which were defined as causing end-organ damage. 12 months
Secondary Limb Salvage Rate Limb Salvage is defined as the freedom from secondary major amputation 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05040958 - Carotid Atherosclerotic Plaque Load and Neck Circumference
Recruiting NCT05680935 - microRNAs in the Diagnosis of Atherosclerotic Plaque Instability N/A
Recruiting NCT04955015 - Associations of Carotid Plaque Characteristics With Brain Perfusion and Cognitive Function in Patients Undergoing CEA
Recruiting NCT06091319 - Florbetaben for Imaging of Vascular Amyloid
Recruiting NCT06211127 - Safety and Efficacy of Cold Laser Plaque Ablation for Lower Limb Arterial Stenosis and Occlusive Lesions N/A
Withdrawn NCT05908513 - NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM Phase 1
Suspended NCT03928769 - PROGENitors, TELomeres and ARTerial Aging
Not yet recruiting NCT04277702 - Cysteinyl Leukotriene Antagonist in Atherosclerosis Inhibition in Patients After Endovascular Treatment Due to Peripheral Arterial Disease Phase 3
Not yet recruiting NCT04303546 - VOPITB a New Devices to Determine Peripheral Arterial Stiffness: Validation Study
Completed NCT05214872 - The Impact of Selected Factors on the Cardiovascular System in Chronic Kidney Disease
Completed NCT02715830 - Randomized Clinical Trial in Bellow-the-knee Angioplasty. Treatment of One or More Than One Artery. Phase 4
Not yet recruiting NCT06447701 - Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis Phase 3
Recruiting NCT04758650 - Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis Phase 2
Completed NCT04198896 - The Sakakibara Health Integrative Profile of Atherosclerotic-Carcinogenesis Hypothesis (SHIP-AC)
Completed NCT03499496 - Screening for Atherotic Plaques by Ultrasound for Assessing Cardiovascular Risk
Completed NCT05118542 - Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis Phase 3
Completed NCT03962686 - Molecular Mechanisms and Carotid Atherosclerosis
Active, not recruiting NCT04666584 - Optimal Predilatation Treatment Before Implantation of a Magmaris Bioresorbable Scaffold in Coronary Artery Stenosis N/A
Recruiting NCT05797376 - Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation Phase 4
Not yet recruiting NCT04303351 - Periodontitis and Atherosclerotic-related Arterial Stenosis